Larvol Delta - Celea-Therapeutics-Will-Present-Phase-3-Trial-Design-for-Idiopathic-Pulmonary-Fibrosis-and-Key-Insights-from-a-Deupirfenidone-DrugDrug-Interaction-Study-at-the-Upcoming-European-Respiratory-Society-ERS-Congress

deupirfenidone (LYT-100) - Celea Therapeutics

https://www.businesswire.com/news/home/20260825797512/en/Celea-Therapeutics-Will-Present-Phase-3-Trial-Design-for-Idiopathic-Pulmonary-Fibrosis-and-Key-Insights-from-a-Deupirfenidone-Drug-Drug-Interaction-Study-at-the-Upcoming-European-Respiratory-Society-ERS-Congress?

Aug 25, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next